Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sami Abdul Jawad

Critical Care Medicine Falls Church, VA Medical Doctor

NPI 1487930905 CMS profile 203756

3300 Gallows Rd, Falls Church, VA 22042

Open in the dashboard

General payments

$192,652

317 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sami Abdul Jawad of Falls Church, VA is reported in the CMS Open Payments database as having received $192,652 across 317 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,950 22
2024 General $10,463 16
2023 General $20,272 33
2022 General $35,119 50
2021 General $36,910 55
2020 General $24,817 60
2019 General $49,121 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sami Abdul Jawad
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Sami Abdul Jawad were reported at $15,950. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Sami Abdul Jawad Critical Care Medicine median Middle half National median
2019 $49,121 $149 $51–$535 $163
2020 $24,817 $110 $30–$325 $114
2021 $36,910 $125 $34–$403 $132
2022 $35,119 $157 $49–$582 $149
2023 $20,272 $162 $56–$621 $160
2024 $10,463 $168 $53–$634 $164
2025 $15,950 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $128,151 152 payments
  2. AstraZeneca Pharmaceuticals LP $57,700 94 payments
  3. Sunovion Pharmaceuticals Inc. $1,897 20 payments
  4. ViiV Healthcare Company $1,600 1 payment
  5. Mylan Specialty L.P. $1,245 5 payments
  6. Pulmonx Corporation $1,235 4 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $194 9 payments
  8. Mallinckrodt Hospital Products Inc. $146 6 payments
  9. United Therapeutics Corporation $113 6 payments
  10. Pfizer Inc. $78 4 payments
  11. Other $292 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $177,077 94 payments
  2. Travel and Lodging $8,386 42 payments
  3. Food and Beverage $4,595 167 payments
  4. Consulting Fee $2,448 5 payments
  5. Education $146 9 payments
Products named General payments · program years 2019–2025
  1. NUCALA Immunology $61,768 72 payments
  2. TRELEGY ELLIPTA $45,179 56 payments
  3. FASENRA Respiratory $31,134 47 payments
  4. FASENRA Respiratory $11,931 19 payments
  5. BREZTRI $11,010 18 payments
  6. NUCALA Respiratory $8,001 17 payments
  7. LONHALA MAGNAIR $1,867 17 payments
  8. DALIRESP $1,616 4 payments
  9. BREZTRI AEROSPHERE $1,288 6 payments
  10. Yupelri $1,245 5 payments
  11. Other $3,761 98 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,281

Median for Pulmonary Disease: 936

Drug cost

$699,306

Median for Pulmonary Disease: $487,987

Branded share of claims

45.8%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aralast Np Alpha-1-Proteinase Inhibitor Brand 14 $243,247
Ofev Nintedanib Esylate Brand 12 $155,709
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 177 $125,633
Nucala Mepolizumab Brand 19 $69,849
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 48 $38,697
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 27 $20,293
Spiriva Handihaler Tiotropium Bromide Brand 20 $9,850
Breo Ellipta Fluticasone/Vilanterol Brand 14 $6,028
Incruse Ellipta Umeclidinium Bromide Brand 16 $5,626
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 11 $5,094

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$69,392

Medicare's payments for the services billed

Medicare patients

410

Average age 73

Services billed

1,083

195 women, 215 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 55%
Arthritis 53%
Diabetes 50%
Ischemic heart disease 46%
Heart failure 41%
Chronic kidney disease 39%
Atrial fibrillation 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $10,463
$10,463 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

317 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record